



Xgene Pharmaceutical Inc. announced achievement of the target patient enrollment in the phase II clinical trial of XG005 oral tablet in the treatment of pain associated with Osteoarthritis.

On April 8, 2024, Xgene Pharmaceutical Inc. (hereinafter referred to as Xgene) announced that the phase II clinical trial of XG005 oral tablet in osteoarthritis pain of the knee has completed its target enrollment of 325 subjects. The last patient's visit is expected in May with top line results expected to be reported in August 2024. The trial is led by the Peking University People's Hospital and involves 26 hospital sites in China.

Dr. Leon Jiang, Chief Medical Officer and Senior Vice President of Xgene Pharmaceutical Inc. emphatically points out that the enrollment of all subjects was successfully achieved due to unremitting efforts of the Xgene's team despite the COVID-19 restrictions in China at the time of the initiation of the project. "In the future, XG005 will not only be used to treat OA patients and cancer pain patients but is also expected to provide an effective and safe clinical treatment for a wide range of painful conditions." – said Dr. Jiang.

Dr. Feng Xu, Co-founder, Chief Operating Officer, and Chief Scientific Officer of Xgene Pharmaceutical Inc. emphasized that XG005 is a new non-opioid oral analgesic that has the characteristics of treating both inflammatory and nerve pain. "For most kinds of acute and chronic pain, XG005 can more effectively inhibit pain signals and achieve better clinical efficacy through its dual-action analgesic effect" - said Dr. Xu.

Dr. Gene Hsu, Co-founder and CEO of Xgene Pharmaceutical Inc., express thanks to Xgene's team for their great efforts and stressed that "Xgene has taken a big step forward to global commercialization by pursuing simultaneous late stage of clinical development of XG005 in China and the United States". Furthermore, the team is also actively progressing with other pipeline products, completing the Phase 1b/2a clinical trial of XG004 topical gel in the Royal Adelaide Hospital in Australia and initiating the Phase I clinical trials for XG2002, a novel oral small molecule selective antagonist targeting the TRPM8 receptor. "The company will continue to focus on the research and development of innovative analgesic products with strong commitment to providing patients with safe and effective treatments, while creating affordable analgesic options for medical institutions, and contributing to the development of the global analgesic field!" – said Dr. Hsu.



About XG005

XG005, independently developed by Xgene, is a new chemical entity (NCE) and a novel non-opioid dual-action conjugate of an NSAID and a calcium channel inhibitor. It simultaneously targets the anti-inflammatory and neuropathic pathways of pain and, through its unique multi-modal analgesic mechanism, can inhibit pain signals more effectively to achieve better clinical efficacy in a wide range

of painful conditions. Xgene is pursuing development of XG005 in several indications including acute pain (Phase IIb/III in post-surgical pain the US), chronic pain (Phase II in OA pain in China), and chronic cancer pain (Phase II in China).

About Xgene

Xgene Pharmaceutical Inc. is a clinical stage, venture capital-backed, international company utilizing linker technology to create novel, multimodal, conjugated molecules for the treatment of pain and other neurological conditions. Xgene's linker technology overcomes the challenges of the multimodal therapy approach, and offers potentially better, safer, and more efficient treatments. Current programs are focused on dual-action NCEs with improved analgesic efficacy and tolerability and the pipeline comprising late-stage clinical programs as well as assets in discovery and preclinical development. Xgene has gained recognition and support from leading investment institutions such as Morningside Capital, TF Capital, Ping'an Venture Capital, Hengxu Capital, CITIC Securities and other investment institutions.